TL;DR
This paper presents a novel fragment-based drug discovery approach to target protein-protein interactions (PPIs), specifically the interaction between BRCA2 and RAD51, crucial for DNA repair. By engineering a stable, monomeric form of RAD51 and employing a multi-stage biophysical screening pipeline, they successfully identified small molecule fragments that bind to a challenging, shallow pocket on the RAD51 surface, paving the way for new therapeutic strategies.
What Problem Does This Paper Address?
Targeting protein-protein interactions (PPIs) with small molecules is a major hurdle in drug discovery. Unlike enzyme active sites, PPI interfaces are often large, flat, and lack well-defined pockets, making them difficult for small molecules to bind to with sufficient affinity and selectivity. The interaction between the tumor suppressor BRCA2 and the DNA recombination enzyme RAD51 is critical for repairing DNA double-strand breaks. Disrupting this interaction is hypothesized to sensitize cancer cells to radiation and genotoxic drugs, making it a promising therapeutic target. However, no validated inhibitors or fragments for this specific PPI had been reported, highlighting the need for new strategies to tackle such challenging targets.
Methods
The researchers developed a multi-stage screening pipeline combining several biophysical techniques.
- Protein Engineering: To overcome the self-associating nature of RAD51, they engineered a monomeric surrogate using a thermostable archaeal orthologue, RadA. This involved removing the N-terminal domain responsible for filament formation and introducing specific mutations to "humanize" the binding pocket, creating the "MAYSAM" RadA mutant.
- Thermal-Shift Screening: This was the initial, high-throughput step. It monitors the melting temperature (Tm) of the protein in the presence of fragments. Fragments that bind and stabilize the protein cause an increase in Tm, indicating a potential hit.
- Saturation Transfer Difference (STD) NMR Spectroscopy: This technique was used for fragment validation. It detects weak binding by observing signals from the ligand only when it's in close proximity to the protein. Competitive STD NMR was employed using a "reporter" ligand (5-hydroxyindole) to identify other fragments that compete for the same binding site.
- Isothermal Titration Calorimetry (ITC): This is a gold-standard biophysical technique used to quantify the binding affinity (Kd) of validated fragments to the protein. Competitive ITC experiments were also performed to further confirm binding site occupancy.
- X-ray Crystallography: This was the final validation step, providing definitive structural evidence of fragment binding and revealing the precise mode of interaction within the protein's binding pocket.
Datasets
Not discussed in the paper. The study utilized a library of 1249 fragments for the initial thermal-shift screen and a smaller library of 42 fragments for the subsequent STD NMR screening.
Key Insights and Ideas
- Engineering a Stable PPI Target: The successful creation of a monomeric, stable RAD51 surrogate (MAYSAM RadA) is a significant achievement, enabling fragment screening against a challenging PPI target that is otherwise difficult to work with in its native form.
- Fragment Binding to Shallow Pockets: The paper demonstrates that even shallow surface pockets, like the one accommodating the phenylalanine side chain in the FXXA motif, can be effectively targeted by small molecule fragments. This expands the perceived "druggable" space for PPIs.
- Sequential Validation Pipeline: The multi-stage approach, starting with high-throughput thermal-shift screening and progressing through competitive NMR and ITC to crystallography, provides a robust method for filtering out false positives and ensuring that only well-validated hits are pursued.
- Reporter Ligand Strategy: The use of a "reporter" ligand in competitive STD NMR proved highly effective in ranking fragment potencies and identifying new binders that compete for the same site, offering a more informative screen than direct STD experiments.
- Structural Basis for Fragment Binding: X-ray crystallography provided crucial insights into how fragments interact with the protein, revealing hydrogen bonding and hydrophobic interactions that anchor them in the binding pocket, offering clear directions for chemical elaboration.
Key Results
- Fragment Hits Identified: The initial thermal-shift screen identified 96 compounds with a significant shift. Further validation led to the identification of several fragment hits, including 5-hydroxyindole (1) and 5-methylindole (2) from the thermal-shift screen, and 2-aminobenzothiazole (6), L-methylester tryptophan (8), naphth-1-ol (9), and naphth-2-ol (10) from the STD NMR screens.
- Binding Affinities: The identified fragments exhibited typical fragment binding affinities, with Kd values in the millimolar range (e.g., fragment 6 with Kd = 0.73 mM, fragment 10 with Kd = 0.46 mM).
- Ligand Efficiencies: Fragments showed encouraging ligand efficiencies (LE), with values ranging from 0.14 to 0.42, indicating good binding energy relative to their size.
- Structural Confirmation: X-ray crystallography confirmed that these fragments bind within the shallow phenylalanine pocket of the MAYSAM RadA protein, interacting with key residues.
Limitations and Future Work
- Fragment Potency: The identified fragments have low millimolar affinities, which are typical for initial fragment hits but require further chemical elaboration to achieve drug-like potencies.
- Shallow Binding Pocket: While the paper demonstrates that shallow pockets can be targeted, the limited depth of the binding site presents a challenge for achieving high affinity and selectivity.
- Future Work: The authors suggest that the identified fragments provide promising starting points for chemical elaboration. Future work will focus on growing these fragments to develop more potent lead molecules. The methodology developed is expected to be broadly applicable to other challenging PPI targets. The authors also highlight the importance of a robust platform of orthogonal biophysical assays for successful fragment-based drug discovery programs.
Summary updated